<DOC>
	<DOC>NCT00617565</DOC>
	<brief_summary>This trial is conducted in Asia. The aim of this trial is to investigate the efficacy of biphasic insulin aspart 30 on postprandial glycaemic control.</brief_summary>
	<brief_title>Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart, insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin, Long-Acting</mesh_term>
	<mesh_term>Insulin, Isophane</mesh_term>
	<criteria>Type 1 or 2 diabetes for at least 3 months Stabilised on current treatment with premixed human insulin for at least 4 weeks Body mass index (BMI) between 1840 kg/m2 HbA1c below 13.0% Able and willing to perform selfblood glucose monitoring The receipt of any investigational drug within the last three months prior to this trial Has a history of drug abuse or alcohol dependence within the last 5 years Active proliferative retinopathy requiring laser or surgical intervention within the last year Recurrent major hypoglycaemia as judged by the Investigator Known or suspected allergy to trial product or related product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>